With FDA Nod, Bayer’s Lynkuet Enters US Market for Nonhormonal Menopause Symptom Meds

Following a slight delay earlier this year—and a world-first green light in the United Kingdom over the summer—Bayer has clinched an FDA nod to bolster the limited arsenal of nonhormonal treatments for one of the most common symptoms of menopause. This approval marks a significant milestone for Bayer as it introduces Lynkuet to the U.S. market, addressing an unmet need for effective menopause symptom relief without the use of hormones.

The entry of Lynkuet into the U.S. market comes at a time when healthcare providers and patients are increasingly seeking alternatives to hormonal therapies, which can carry various risks and side effects. The FDA’s endorsement reflects a growing recognition of the importance of expanding treatment options for menopause symptoms, particularly for women who are contraindicated for hormone therapy. This development not only enhances Bayer’s portfolio but also positions the company as a key player in the evolving landscape of menopause management.